News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

SUBSCRIBE

SUBSCRIBE

News
Insights
Jobs
Career Advice
Companies
Hotbeds
More

Search Query

Search Results

Looking for jobs? Search jobs

2,355 Results

Type

Article (324)
Company Profile (1)
Press Release (2030)

Section

Business (758)
Career Advice (8)
Deals (141)
Drug Development (278)
Employer Resources (1)
FDA (63)
Job Trends (85)
News (1152)
Policy (89)

Tag

Date

Today (1)
Last 7 days (1)
Last 30 days (4)
Last 365 days (104)
2025 (27)
2024 (106)
2023 (111)
2022 (142)
2021 (180)
2020 (170)
2019 (208)
2018 (141)
2017 (142)
2016 (139)
2015 (147)
2014 (114)
2013 (129)
2012 (103)
2011 (107)
2010 (71)

Location

Africa (7)
Asia (86)
Australia (8)
California (2)
Canada (2)
Colorado (1)
Delaware (1)
Europe (181)
Indiana (1)
Maryland (1)
Massachusetts (31)
Minnesota (1)
Nebraska (2)
New Jersey (5)
New York (2)
North Carolina (1)
Northern California (2)
Ohio (1)
Pennsylvania (9)
South America (8)

Filters

Type

Article (324)
Company Profile (1)
Press Release (2030)

Section

Business (758)
Career Advice (8)
Deals (141)
Drug Development (278)
Employer Resources (1)
FDA (63)
Job Trends (85)
News (1152)
Policy (89)

Tag

Date

Today (1)
Last 7 days (1)
Last 30 days (4)
Last 365 days (104)
2025 (27)
2024 (106)
2023 (111)
2022 (142)
2021 (180)
2020 (170)
2019 (208)
2018 (141)
2017 (142)
2016 (139)
2015 (147)
2014 (114)
2013 (129)
2012 (103)
2011 (107)
2010 (71)

Location

Africa (7)
Asia (86)
Australia (8)
California (2)
Canada (2)
Colorado (1)
Delaware (1)
Europe (181)
Indiana (1)
Maryland (1)
Massachusetts (31)
Minnesota (1)
Nebraska (2)
New Jersey (5)
New York (2)
North Carolina (1)
Northern California (2)
Ohio (1)
Pennsylvania (9)
South America (8)

2,355 Results for "sage bionetworks".

Sort By

Legal

Sage Sues Partner Biogen After Unsolicited Takeover Offer

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.

January 21, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions

Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.

January 27, 2025
·
1 min read
·
Annalee Armstrong
Neuroscience

Biogen Submits Offer to Buy Embattled Partner Sage

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of Sage Therapeutics have fallen by more than 90%.

January 13, 2025
·
3 min read
·
Heather McKenzie
Podcast

RFK Jr. Faces the Senate, Sage Rebuffs Biogen, Obesity Space Expands, More

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees more action with new company launches, IPOs and fresh data; and experts get ready for an important era in the Duchenne muscular dystrophy space.

January 29, 2025
·
1 min read
·
Heather McKenzie
Business

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference. Meanwhile, Biogen proposes to acquire struggling neuro partner Sage, and obesity dominates discussions as Pfizer goes “all in.”

January 15, 2025
·
1 min read
·
Heather McKenzie
Editorial

Embattled Sage Dealt Deeper Blow With Huntington’s Failure

Sage Therapeutics discontinued development of its lead candidate dalzanemdor after a third clinical failure, leading analysts to question the biotech’s future profitability.

November 25, 2024
·
4 min read
·
Heather McKenzie
Huntington’s disease

Sage Scraps Huntington’s Hopeful After Disappointing Phase II Data

After previously failing studies in Parkinson’s and Alzheimer’s, dalzanemdor’s latest stumble in Huntington’s disease has pushed Sage Therapeutics to pull the plug on the NMDA receptor modulator.

November 20, 2024
·
2 min read
·
Tristan Manalac
Podcast

Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million in radiopharma while selling its consumer health unit; Novo Nordisk’s positive Rybelsus results in cardiovascular disease; and more.

October 23, 2024
·
1 min read
·
Heather McKenzie
Earnings

Sage Touts Q3 Zurzuvae Revenue Growth, Will Not Seek MDD Indication

On its third-quarter earnings call Tuesday, Sage highlighted the launch of its Biogen-partnered postpartum depression drug Zurzuvae but said it will stop pursuing approval for major depressive disorder, which the FDA previously denied.

October 30, 2024
·
2 min read
·
Heather McKenzie
Layoffs

Sage Therapeutics Will Lay Off 33% of Employees, Including Over Half of R&D

As part of a strategic reorganization intended in part to support the ongoing launch of its postpartum depression drug, Sage Therapeutics is cutting more than 165 employees.

October 17, 2024
·
2 min read
·
Angela Gabriel

1 of 236

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.

Explore
About
More

© 1985 - 2025 BioSpace.com. All rights reserved.

twitter
instagram
facebook
linkedin